The von Willebrand factor (vWF) is a large multimeric glycoprotein with binding domains for hemostatic components, such as GP Ibα of the platelet vWF receptor complex glycoprotein (GP) Ib-V-IX, the platelet receptor for fibrinogen and vWF GP IIb-IIIa (integrin α IIb β 3 ), collagen, and factor VIII:C. The vWF mediates platelet adhesion to injured endothelium by binding to GP Ibα and to subendothelial collagen. In addition, Summary: Determination of von Willebrand factor activity is required for diagnosis and classification of von Willebrand disease. In addition, von Willebrand factor activity can be of prognostic relevance in several clinical entities including thromboembolic and cardiovascular disorders in which elevated activity correlates with a poor prognosis. The HaemosIL™ assay (Instrumentation Laboratory GmbH, Munich, Germany) provides a new fully automated procedure for determination of von Willebrand factor activity. This assay measures binding of the von Willebrand factor to GP Ibα of the platelet glycoprotein complex Ib-V-IX. In our study, we analyzed 300 samples including those of patients with hereditary von Willebrand disease. The results obtained with the HaemosIL™ assay were compared to von Willebrand factor activities determined by established procedures. Activities determined with HaemosIL™ correlated with those activities determined as ristocetin cofactor (r = 0.88, p < 0.0001), collagen-binding (r = 0.93, p < 0.0001), and GP Ib-binding (r = 0.91, p < 0.0001). The comparability of results obtained by HaemosIL™ and the GP Ib-binding ELISA were excellent ([HaemosIL™] = 0.96 ∞ activity [GP Ib-binding ELISA] + 10.7), whereas activities determined by ristocetin cofactor or collagen-binding revealed more variance. Like the other assays, the HaemosIL™ failed to indicate a loss of high-molecular-weight von Willebrand factor multimers. The HaemosIL™ assay can replace the GP Ib-binding ELISA for the determination of von Willebrand factor activity. Advantages of this assay include accuracy of results, full automation, and, thus, broad availability. Since the assay does not predict the absence of high-molecular-weight multimers, multimeric analysis remains the procedure of choice for the differentiation of functional defects.
vWF protects factor VIII:C from premature cleavage and, thus, plays a crucial role in plasmic hemostasis (1) .
When the vWF is absent, reduced, or dysfunctional, patients may exhibit a bleeding disorder termed von Willebrand disease (vWD). In this setting, a complex diagnostic procedure including determination of vWF antigen levels, assessment of vWF activity, and analysis of the multimeric pattern is required for further classification (2) . In contrast to reduced function in vWD, elevated antigen levels and increased activity of this adhesive protein are found in inflammation and were reported to indicate a poor prognosis in patients with vasculitis (3), pulmonary hypertension (4), cardiovascular disease (5) , and heart failure (6) . Thus, determination of vWF activity is important, not only in the context of vWD, but also for the characterization of the acute-phase response and, possibly, for risk stratification in cardiac and vascular disease and pulmonary hypertension.
Recently, the HaemosIL™ assay (Instrumentation Laboratory GmbH, Munich, Germany), a fully automated turbimetric method for determination of vWF activity was introduced. This assay measures the binding of vWF to GP Ibα of the platelet receptor complex GP Ib-V-IX.
In our study, we compared vWF activities determined by HaemosIL™ assay with activities obtained by established functional vWF assays, particularly the ristocetin cofactor method and ELISAs for GP Ib-binding and collagen-binding. In addition, the sensitivity and specifity of HaemosIL™ with regard to presence or absence of high-molecular-weight vWF multimers was assessed and compared to the other assays.
SAMPLES AND METHODS
For this study, 300 blood samples consecutively referred for the determination of vWF antigen levels and activity were examined. Measurements were performed immediately or plasma samples were stored at -80°C until analysis.
The HaemosIL™ vWF assay employs a latex-adsorbed monoclonal murine antibody directed against the GP Ibα binding domain of the vWF. The latex particles are agglutinated proportionally to the GP Ibα binding activity of vWF in the sample. Agglutination is quantified by using a turbimetric assay at a wave length of 405 nm. Analysis is performed with an ACL 10000 (Instrumentation Laboratory GmbH, Munich, Germany).
GP Ib binding activity of the vWF was in parallel determined by an ELISA using the vWF Activity Kit (Axis Shield Diagnostics Ltd., Dundee, Scotland) according to the manufacturer's instructions. For the determination of the ristocetin cofactor, BC von Willebrand Reagent™ (Dade Behring, Marburg, Germany) was used and the samples were analyzed by use of a Behring Coagulation Timer (Dade Behring, Marburg, Germany) according to the manufacturer's instructions. Collagen-binding activity was determined with use of the vWF:CB ELISA™ (Progen Biotechnik GmbH, Heidelberg, Germany).
Statistical Analysis
The SAS statistical package (version 8.02, SAS Institute, Cary, NC, USA) was applied for all statistical analyses. Standard procedures were used to assess the correlation of vWF activities determined with HaemosIL™ and the other assays (Spearman rank-order correlation). The test characteristics for predicting a loss of high-molecular-weight vWF multimers were evaluated by using a logistic regression procedure with presence or absence of vWF multimers as binary response variable. From the fitted model, a predicted event probability (loss of high-molecular vWF multimers) was computed for each observation. The cut-off value was defined as vWF assay activity predicting a loss of high-molecular multimers with a probability of 20%. Assuming different pretest probabilities (10%, 20%, and 50%) for the loss of high-molecular multimers, the posterior probabilities for false-positive and negative results were computed. Statistical significance was assumed at a p value below 0.05.
RESULTS

Comparison of the HaemosIL™ Assay with Assays of von Willebrand Factor Activity
The correlations of vWF activities determined with the HaemosIL™ assay and activities determined with the other assays are shown in Fig. 1 . vWF activities determined with the HaemosIL™ assay correlated strongly with those determined as GP Ib-binding (r = 0.91, p < 0.0001, n = 249), collagen-binding activity (r = 0.93, p < 0.0001, n = 156), and ristocetin cofactor activity (r = 0.88, p < 0.0001, n = 297). 
Prediction of a Loss of High-Molecular-Weight Multimers by HaemosIL™
The results for vWF activity determined with HaemosIL™ in patients with presence (A) or absence (B) of high-molecular-weight multimers are shown in Fig. 2 . Patients with presence of high-molecular-weight multimers had significantly higher activities (98 ± 44% vs. 56 ± 44%, p < 0.05). Further statistical analyses were performed to assess the suitability of the HaemosIL™ to predict a loss of high-molecular vWF multimers. The cut-off value defined as vWF assay activity predicting a loss of high-molecular vWF multimers with a probability of 20% was 34% for the HaemosIL™ assay, 39%, for the GP Ib-binding ELISA, 30% for vWF:RCo, and 58% for collagen-binding. The corresponding test characteristics for sensitivity, specificity, falsepositive, and false-negative results and predictive values are given in Table 1 . None of the assays showed sufficient sensitivity or specificity to detect or rule out absence of high-molecular vWF multimers.
DISCUSSION
The HaemosIL™ assay is a recently developed latex immunoassay that determines the capacity of vWF to bind to the vWF binding domain located on GP Ibα of the platelet receptor complex glycoprotein (GP) Ib-V-IX. The excellent comparability of activities determined with HaemosIL™ and an ELISA-based GP Ib-binding assay strongly suggests the replacement of the time-consuming ELISA through the new fast, fully automated, and easy-to-perform HaemosIL™ assay. Thus, the determination of GP Ib-binding previously re-stricted to expert laboratories is now available for routine laboratories.
The interaction between GP Ib-V-IX and vWF initiates primary hemostasis. This interaction not only is the first adhesive event of platelets at sites of vascular injury but also facilitates platelet aggregation by activating the platelet fibrinogen receptor GP IIb-IIIa (integrin α IIb β 3 ) (7) and binding of platelets to collagen by activating the collagen receptor GP Ia-IIa (integrin α 2 β 1 ) (8) . Although determination of GP Ib-binding is less established than ristocetin cofactor or collagenbinding activity, this assay should provide additional information regarding vWF function in primary hemostasis.
Owing to their outstanding importance in primary hemostasis, the presence or absence of high-molecular vWF multimers is an important aspect for classification of vWD. Like the other assays currently available, the HaemosIL™ assay has a low predictive value in this setting, even in selected patients with the lowest absolute activities. Thus, multimeric analysis remains necessary to detect or rule out absence of high-molecularweight vWF multimers.
Owing to limitations of each available assay and the heterogeneity of vWD, no single test pro- cedure is sufficient to permit the detection of all vWF variants (9) . In general, methods for routine assessment of vWF activity should be rapid, fully automated, and, thus, easy to perform. Although the commonly used ristocetin cofactor assay provides rapid information and is easy to perform, its usefulness is limited by technical problems including considerable variability and low reproducibility (10) . Assessment of vWF binding to GP Ibα by use of the HaemosIL™ assay could possibly replace ristocetin cofactor as initial approach to vWF function.
Since GP Ib-binding, collagen binding, and ristocetin cofactor assess different functional properties of plasma vWF, the discrepancies of the assay results are not surprising. The variance of the results suggests that none of the assays can replace another to provide identical information. Thus, replacement of any assay by others that are thought to be more reliable and reproducible (11) would potentially impair the characterization of vWF defects. On the contrary, it can be speculated that a combination of two or more different assays would allow a better characterization of vWF function than the use of a single assay.
In summary, the HaemosIL™ assay, which measures binding of vWF to GP Ibα, provides a new, rapid, and easy-to-perform diagnostic tool for the assessment of vWF function that can readily replace the assessment of GP Ib-binding through a time-consuming ELISA. HaemosIL™ is useful for the screening of vWF activity but not suitable to identify an absence of high-molecular-weight vWF multimers. 
